[
    [
        {
            "time": "",
            "original_text": "“瘦身”计划已正式开启！从“买买买”到“归核化”，上市药企这几年经历了什么？",
            "features": {
                "keywords": [
                    "瘦身计划",
                    "买买买",
                    "归核化",
                    "上市药企"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "“瘦身”计划已正式开启！从“买买买”到“归核化”，上市药企这几年经历了什么？",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中生制药跌逾3% 主动卖盘58%暂连跌2日",
            "features": {
                "keywords": [
                    "中生制药",
                    "跌逾3%",
                    "主动卖盘",
                    "连跌2日"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中生制药跌逾3% 主动卖盘58%暂连跌2日",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "安信国际 | 2020医药行业：集采带来不确定性，创新仍是发展主线",
            "features": {
                "keywords": [
                    "安信国际",
                    "医药行业",
                    "集采",
                    "不确定性",
                    "创新"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "安信国际 | 2020医药行业：集采带来不确定性，创新仍是发展主线",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】复星医药(02196-HK)获复星国际控股增持46万股",
            "features": {
                "keywords": [
                    "复星医药",
                    "复星国际",
                    "增持",
                    "46万股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】复星医药(02196-HK)获复星国际控股增持46万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智通港股通持股解析|1月3日",
            "features": {
                "keywords": [
                    "智通港股通",
                    "持股解析"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智通港股通持股解析|1月3日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]